Aerie Pharmaceuticals Profile

64.15
USD 0.05  0.08%
93%
20%

Exercise or conversion by Vicente Anido of 50000 shares of Aerie Pharmaceuticals subject to Rule 16b-3

Aerie Pharmaceuticals insider trading alert for exercise of option (right to buy) by Vicente Anido, Chief Executive Officer, on June 13, 2018. This event was filed by Aerie Pharmaceuticals Inc with SEC on 2018-06-13. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Aerie Pharmaceuticals Summary

Aerie Pharmaceuticals (AERI) is traded on NASDAQ General Markets in USA. It is located in NORTH CAROLINA, U.S.A and employs 160 people. Aerie Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 2.53 B. Aerie Pharmaceuticals conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 39.5 M outstanding shares of which 5.94 M shares are presently shorted by private and institutional investors with about 18.15 trading days to cover. Aerie Pharmaceuti currently holds about 333.98 M in cash with (109.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.46.
Check Aerie Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 64.15HorizonTargetOdds Above 64.15
89.68%30 days 64.15 10.25%
Based on normal probability distribution, the odds of Aerie Pharmaceuticals to move above current price in 30 days from now is about 10.25% (This Aerie Pharmaceuticals probability density function shows the probability of Aerie Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Wellington Management Group LlpCommon Shares5.4 M291.3 M
Vanguard Group IncCommon Shares3.2 M173.7 M
View Aerie Pharmaceuticals Diagnostics

Selected Aerie Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Aerie Pharmaceuticals Against Markets

Risk Adjusted
Performance Score (0 to 100)
29 
Chance of
Financial Distress (0 to 100%)
4 
Equity ratings for Aerie Pharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina. Aerie Pharmaceuticals operates under Drug Manufacturers - Major classification in USA and traded on NASDAQ General Markets. It employs 160 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameAerie Pharmaceuticals
Chairman and CEOVicente AnidoView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
LocationNORTH CAROLINA, U.S.A
Business Address4301 Emperor Boulevard
ExchangeNASDAQ General Markets
CIK Number01337553.0
CUSIP00771V108
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.aeriepharma.com
Contact Number919 237 5300
CurrencyUSD - US Dollar

Current Sentiment - AERI

Aerie Pharmaceuticals Investor Sentiment
Most of Macroaxis users are presently bullish on Aerie Pharmaceuticals. What is your sentiment towards investing in Aerie Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Recommendations

Aerie Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
56.5Buy10Odds
Aerie Pharmaceuticals current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Aerie Pharmaceuticals Analyst Advice  

Earnings

Aerie Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.66March 7, 2017
Aerie Pharmaceuticals normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Aerie Pharmaceuticals Corporate Directors
Julie McHugh Independent Director, MBA
Benjamin McGraw Independent Director, Ph.D
Anand Mehra Director, Ph.D
Check also Trending Equities. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.